(Bloomberg) -- Bicara Therapeutics is working with Morgan Stanley on a US initial public offering, people familiar with the situation said, as the market for first-time share sales is showing signs of normalizing. Most Read from BloombergBiden Asks Donors to Stay Following Disastrous DebateBiden's Defiance Has Democrats Fearing They'll Lose White HouseCLOs Have Too Much Money and Are Running Out of Things to BuyJustice Department to Charge Boeing, Seeks Guilty Plea from PlanemakerSingapore Loses
NEW YORK, June 28, 2024--Morgan Stanley (NYSE: MS) announced that it will increase its quarterly common stock dividend to $0.925 per share from the current $0.85 per share, beginning with the common stock dividend expected to be declared by the Firm’s Board of Directors in the third quarter of 2024.
Morgan Stanley hit with cash-sweep suit. Morgan Stanley pays an interest rate of as little as 0.01% on customers’ uninvested cash in its default bank sweep program. Morgan Stanley declined to comment on the case.